Senores Pharmaceuticals Ltd
Incorporated in 2015, Senores Pharmaceuticals Ltd manufactures and develops affordable and high-quality complex generics certified by global food and drugs authorities[1]
- Market Cap ₹ 2,685 Cr.
- Current Price ₹ 583
- High / Low ₹ 665 / 435
- Stock P/E 46.0
- Book Value ₹ 171
- Dividend Yield 0.00 %
- ROCE 11.4 %
- ROE 11.8 %
- Face Value ₹ 10.0
Pros
- Debtor days have improved from 177 to 114 days.
Cons
- Stock is trading at 3.41 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Company might be capitalizing the interest cost
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of BSE Healthcare BSE SmallCap BSE IPO BSE Allcap
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|
14 | 35 | 215 | 398 | |
12 | 23 | 173 | 309 | |
Operating Profit | 2 | 13 | 42 | 90 |
OPM % | 14% | 36% | 19% | 23% |
0 | 4 | 3 | 19 | |
Interest | 1 | 2 | 9 | 22 |
Depreciation | 1 | 2 | 10 | 17 |
Profit before tax | 1 | 12 | 25 | 71 |
Tax % | 13% | 32% | -31% | 17% |
1 | 8 | 33 | 58 | |
EPS in Rs | 1.01 | 8.59 | 10.31 | 12.72 |
Dividend Payout % | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 204% |
TTM: | 86% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 289% |
TTM: | 85% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
1 Year: | % |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 15% |
Last Year: | 12% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|
Equity Capital | 9 | 10 | 31 | 46 |
Reserves | 28 | 36 | 174 | 740 |
15 | 63 | 258 | 315 | |
8 | 23 | 160 | 126 | |
Total Liabilities | 59 | 131 | 622 | 1,227 |
7 | 27 | 235 | 429 | |
CWIP | 8 | 34 | 97 | 44 |
Investments | 15 | 16 | 0 | 0 |
29 | 53 | 289 | 754 | |
Total Assets | 59 | 131 | 622 | 1,227 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|
-10 | -1 | -20 | -46 | |
-24 | -48 | -54 | -429 | |
36 | 46 | 87 | 573 | |
Net Cash Flow | 2 | -3 | 13 | 98 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|
Debtor Days | 506 | 228 | 191 | 114 |
Inventory Days | 135 | 89 | 129 | 114 |
Days Payable | 324 | 388 | 389 | 136 |
Cash Conversion Cycle | 317 | -71 | -70 | 92 |
Working Capital Days | 414 | 316 | 181 | 220 |
ROCE % | 18% | 12% | 11% |
Documents
Announcements
-
Closure of Trading Window
25 Jun - Trading window closed from July 1, 2025, till 48 hours after June 30 quarter results announcement.
-
Update In Respect Of Our Earlier Intimations Dated March 11, 2025, March 12, 2025, And April 22, 2025 Pursuant To Regulation 30 Of The SEBI (LODR) Regulations, 2015
23 Jun - Acquisition of 540 Havix shares delayed; extension granted till August 23, 2025 due to RBI approval.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
18 Jun - Senores Pharmaceuticals Limited has informed regarding schedule of Analyst/ Investor meeting to be held on June 24, 2025 and June 25, 2025
-
Appointment Of Internal Auditors For FY 2025-26
2 Jun - Senores appoints Sharp & Tannan Associates as internal auditor for FY 2025-26.
-
Board Meeting Outcome for Outcome Of Board Meeting Held On June 02, 2025
2 Jun - Appointment of Sharp & Tannan as internal auditor for FY 2025-26 by Senores Pharmaceuticals.
Concalls
-
May 2025Transcript PPT REC
-
May 2025TranscriptNotesPPT
-
Jan 2025Transcript PPT REC
Business Overview:[1]
SPL is global research driven pharmaceutical company which develops and manufactures
pharmaceutical products for the Regulated Markets of US, Canada and United Kingdom across various therapeutic areas and dosage forms, with a presence in Emerging Markets. Company develops and manufactures specialty, underpenetrated and complex pharmaceutical products. It also manufactures criticalcare injectables and APIs